Investor Relations
Company Overview
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Latest News
Mar 26, 2025 • 7:00 AM EDT
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Mar 20, 2025 • 7:00 AM EDT
Avalo Reports 2024 Financial Results and Recent Business Updates
Feb 24, 2025 • 7:00 AM EST
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Stock Information
Nasdaq: AVTX
Avalo Therapeutics, Inc.
$8.36
Price
0.18 (-2.11%)
Change
35k
Volume
8.04 - 8.99
Day Range
4.60 - 34.46
52 Week Range